)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Bicycle Therapeutics
Bicycle Therapeutics (BCYC) investor relations material
Bicycle Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary29 Oct, 2026
Executive summary
Q3 2026 net loss narrowed to $10.5M from $59.1M YoY, reflecting lower operating costs and $34.1M recognized upon Bayer’s collaboration termination.
March reprioritization focuses resources on nuzefatide pevedotin and next-generation conjugates; planned actions are expected to reduce annual operating expenses by ~50%.
Financial highlights
Q3 collaboration revenue was $34.1M vs. $11.7M YoY; 9M revenue was $35.6M vs. $24.6M, with Bayer termination-related recognition driving the increase.
Q3 operating expenses fell to $47.5M from $77.3M YoY; 9M expenses fell to $169.1M from $247.0M, reflecting lower R&D and G&A spending.
Q3 net loss was $10.5M vs. $59.1M; 9M net loss was $121.6M vs. $198.8M.
9M operating cash use was $155.8M vs. $230.3M; cash, cash equivalents and restricted cash totaled $470.0M at September 30, 2026.
Outlook and guidance
Cash and cash equivalents of $469.9M are expected to fund operating expenses and capital expenditures for at least 12 months from filing; other Q3 materials project runway into 2030.
Expenses are expected to decrease near term from cost savings and reprioritization, but may rise with continued clinical development, pipeline expansion and potential commercialization preparation.
Collaboration revenue is expected to decline near term after Bayer’s September 2026 termination; future revenue may vary with service activity, milestones, options and partner payments.
Further nuzefatide updates and Duravelo-2 survival data are expected in 2027; the BT1702 company-sponsored clinical trial is expected to begin in 2H 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Bicycle Therapeutics
- Promising clinical data and strategic advances position the pipeline for key milestones in 2026.BCYC
Corporate presentation - Net loss narrowed on lower expenses; $33.2M deferred revenue and strong cash runway into 2030.BCYCQ2 2026
- Zelanectide pevedotin advances with strong safety, pivotal trial milestones, and pipeline expansion.BCYCMorgan Stanley 23rd Annual Global Healthcare Conference
- Cost-saving measures and clinical progress extended cash runway into 2030 despite flat net loss.BCYCQ1 2026
- Nine key proposals, including director elections and compensation, recommended for approval at the 2026 AGM.BCYCProxy filing
- AGM proposals cover director elections, executive pay, auditor appointments, and governance policies.BCYCProxy filing
- Strategic pipeline shift and cost cuts extend cash runway to 2030; FY 2025 net loss $219M.BCYCQ4 2025
- First human imaging confirms strong tumor targeting and clinical promise for BRCs.BCYCStatus Update
- Multiple oncology assets advance toward key milestones, backed by strong financial runway.BCYCGoldman Sachs 45th Annual Global Healthcare Conference
Next Bicycle Therapeutics earnings date
Q4 202619 Feb, 2027
Bicycle Therapeutics
Next Bicycle Therapeutics earnings date
Q4 202619 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycle molecules. These molecules are fully synthetic short peptides constrained by small molecule scaffolds, forming two loops that stabilize their structure. This design allows them to bind to targets with high affinity and selectivity, making them promising candidates for drug development, particularly in areas where existing therapeutics are lacking. Bicycle Therapeutics is headquartered in Cambridge, UK, with significant operations in Cambridge, Massachusetts. Its shares are listed on NASDAQ.